HAEMATOLOGY

Clinical Trials 

Click on button to go to trial details:

  ALL TRIALS   ALL5  

  AML TRIALS   ANTISOMA   RICT IN AML      

  CLL TRIALS  CONTINUUM   OFOCIR - CLL5   ORIGIN - CLL008   ROCHE - CLL11

  CML TRIALS   TIDEL2 

  MYELOMA TRIALS   FIRST    VANTAGE

  NHL TRIALS   BRIGHT

  PNH TRIALS   PNH

  THROMBOCYTHAEMIA TRIALS   PT1   

  TRANSPLANT TRIALS   ZOMETA                                                                     

Acronym Study Title Ethics Reference Principle Investigator Trial
Co-ordinator		 Study Status
ACUTE LYMPHOBLASTIC LEUKAEMIA        

ALL5
(Dasatinib for Ph+ ALL)
 		 A PHASE II STUDY OF DASATINIB COMBINED WITH INDUCTION  CHEMOTHERAPY IN PREVIOUSLY UNTREATED DE NOVO PHILADELPHIA + ACUTE LYMPHOBLASTIC LEUKAEMIA   Dr Andrew Butler Jo Sanders open to accrual
ACUTE MYELOID LEUKAEMIA        

ANTISOMA
(Relapsed or Refractory AML)		 AN OPEN LABEL RANDOMIZED CONTROLLED PHASE II STUDY OF AS1411 COMBINED WITH CYTARABINE IN THE TREATMENT OF PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE MYELOID LEUKAEMIA.
PROTOCOL NUMBER: AS1411-C-203		   Dr Ruth Spearing Jo Sanders open to accrual
RICT IN AML allo stem cell transplantation with reduced conditioning (RICT) versus best standard of care in AML in first complete remission. 
PROTOCOL NUMBER: TRALG1/02		 URB/
06/06/043		 Dr Ruth Spearing Jo Sanders open to accrual
CHRONIC LYMPHOCYTIC LEUKAEMIA        

CONTINUUM
(Lenalidomide for CLL maintenance)		 A PHASE 3, MULTICENTRE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CLL FOLLOWING SECOND-LINE THERAPY.
PROTOCOL NUMBER: CC-5013-CLL-002		   Dr Steve Gibbons Jo Sanders open to accrual

OFOCIR - CLL5
(First line therapy FCR 65+)

 

 A RANDOMIZED, OPEN-LABEL MULTICENTRE, PHASE2/3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUMILIXIMAB IN COMBINATION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB ALONE IN SUBJECTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA.   Dr Peter Ganly Jo Sanders open to accrual
ORIGIN -CLL008

 

 A PHASE 3, MULTICENTRE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) VERSUS CHLORAMBUCIL AS FIRST LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA.
PROTOCOL NO. CC-5013-CLL-008		   Dr Steve Gibbons Jo Sanders open to accrual
 ROCHE - CLL11 AN OPEN-LABEL, MULTI-CENTRE, THREE ARM RANDOMISED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF RO5072759 + CHLORAMBUCIL (GClb), RITUXIMAB + CHLORAMBUCIL (RClb) OR CHLORAMBUCIL (Clb) ALONE IN PREVIOUSLY UNTREATED CLL PATIENTS NOT ELIGIBLE FOR FLUDARABINE-BASED CHEMOIMMUNOTHERAPY.
PROTOCOL NO:CLL11 (B021004D)		   Dr Andrew Butler Jo Sanders open to accrual
CHRONIC MYELOID LEUKAEMIA        
TIDEL2
   (CML9)		 A PHASE II STUDY IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA OF INITIAL INTENSIFIED IMATINIB THERAPY AND SEQUENTIAL DOSE-ESCALATION FOLLOWED BY TREATMENT WITH NILOTINIB IN SUBOPTIMAL RESPONDERS TO DETERMINE THE RATE OF DURATION OF MAJOR MOLECULAR RESPONSE.
PROTOCOL NUMBER: CML9		 MEC/
07/10/132		 Dr Andrew Butler Jo Sanders open to accrual
MULTIPLE MYELOMA        

FIRST
(First line therapy MPT v Len/Dex)		 A PHASE III, RANDOMISED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 4-WEEK CYCLES VERSUS THE COMBINATION OF MELPHALAN, PREDNISONE AND THALIDOMIDE GIVEN FOR 12 6-WEEK CYCLES IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA WHO ARE EITHER 65 YEARS OF AGE OR OLDER OR NOT CANDIDATES FOR STEM CELL TRANSPLANTATION.
PROTOCOL NUMBER: IFM07-01		   Dr Liam Fernyhough Jo Sanders open to accrual

VANTAGE
(Relapsed Valcade + Vorinostat)		 An International, Multicenter, Randomized, Double-Blind, Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma.
PROTOCOL NUMBER: MK-0683-088		   Dr Peter Ganly Jo Sanders open to accrual

NON-HODGKIN'S LYMPHOMA

       

BRIGHT
(Indolent NHL)		 AN OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP STUDY OF BENDAMUSTINE HYDROCHLORIDE AND RITUXIMAB (BR) COMPARED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE (R-CVP) OR RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (R-CHOP) IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA (NHL) OR MANTLE CELL LYMPHOMA (MCL).
PROTOCOL NUMBER: C18083/3064/NL/MN		   Dr Peter Ganly
 		 Jo Sanders open to accrual
PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA        
PNH  OBSERVATIONAL REGISTRY COMPILING DATA ON THE HISTORY AND MANAGEMENT OF PATIENTS DIAGNOSED WITH PNH URA/
06/02/001		 Dr Ruth Spearing Jo Sanders open to accrual
PRIMARY THROMBOCYTHAEMIA        
PT1  A RANDOMISED TRIAL TO COMPARE ASPIRIN VERSUS HYDROXYUREA/ASPIRIN IN 'INTERMEDIATE RISK' PT AND ASPIRIN ONLY WITH OBSERVATION IN 'LOW RISK' PT
PROTOCOL NUMBER: PT1		 00/11/157 Dr Steve Gibbons Jo Sanders open to accrual
TRANSPLANT (SUPPORTIVE CARE)        

ZOMETA
(Post Allo SCT)		 A TREATMENT ALGORITHM EVALUATING THE EFFECT OF ZOLEDRONIC ACID ON BONE MINERAL DENSITY LOSS AFTER ALLOGENIC STEM CELL TRANSPLANTATION. MEC/09/02/010 Dr Peter Ganly Jo Sanders open to accrual